The US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin. ...
Tags: FDA, sNDA, pharmaceutical product, clinical development
Boehringer Ingelheim and Eli Lilly and Company have received European Commission marketing authorization for Jentadueto (linagliptin/metformin hydrochloride) tablets. Jentadueto is a new, single-tablet treatment option, taken twice daily, ...
Tags: marketing authorization, Jentadueto tablets, glycemic control